Phosphorylation of FOXN3 by NEK6 promotes pulmonary fibrosis through Smad signaling.

Summary

This study identifies a NEK6–FOXN3–Smad axis that governs profibrotic transcription. NEK6 phosphorylates FOXN3, leading to its degradation, loss of Smad4 ubiquitination, and sustained Smad complex activity, thereby promoting pulmonary fibrosis; clinical samples show inverse FOXN3 and Smad4 expression.

Key Findings

• FOXN3 suppresses pulmonary fibrosis by inhibiting Smad transcriptional activity and promoting Smad4 ubiquitination, disrupting Smad2/3/4 chromatin binding.
• NEK6 phosphorylates FOXN3 at S412/S416 under profibrotic stimuli, triggering FOXN3 degradation and unleashing Smad transcriptional activity.
• Clinical fibrosis samples exhibit an inverse expression relationship between FOXN3 and Smad4, supporting translational relevance of the NEK6–FOXN3–Smad axis.

Clinical Implications

Pharmacologic NEK6 inhibition or strategies that stabilize FOXN3 could attenuate profibrotic Smad signaling; FOXN3/Smad4 expression patterns may serve as biomarkers for disease activity or treatment response in idiopathic pulmonary fibrosis.

Limitations

• Predominantly preclinical mechanistic evidence with no interventional validation using NEK6 inhibitors in vivo reported in the abstract.
• Sample sizes and in vivo effect sizes are not detailed in the abstract, limiting appraisal of robustness and generalizability.

Future Directions

Test NEK6 inhibitors or FOXN3-stabilizing approaches in animal models of pulmonary fibrosis; validate FOXN3/Smad4 as biomarkers in prospective IPF cohorts and explore safety-efficacy tradeoffs of targeting this axis.